What does the evidence say about Amla Lipid Profile Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Amla Lipid Profile Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background Dyslipidemia, marked by abnormal lipid levels, significantly increases the risk of cardiovascular diseases. [Jagalurappa K (2025); evidence level 4] - Effective management of these lipid abnormalities is essential for reducing cardiovascular risk. [Jagalurappa K (2025); evidence level 4] - Results Amla extract over a period of 90 days significantly reduced triglyceride ( P = 0.007), total cholesterol ( P P = 0.006), VLDL ( P = 0.014), and AIP ( P P = 0.967) and fasting blood sugar ( P = 1.00). [Jagalurappa K (2025); evidence level 4] - In addition, high blood plasma triglyceride (TG) levels add another independent risk factor for the development of coronary artery disease (CAD) and cardiovascular events (;;). [Hermans Michel P. (2023); evidence level 4] - Among the key risk factors of secondary hypercholesterolemia are excessive consumption of saturated fats, trans-fatty acids, cholesterol-rich diets, and a sedentary lifestyle. [Hermans Michel P. (2023); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.